Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinflunine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 0.77 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 0.77 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 0.77 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 0.77 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 0.77 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 0.77 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 0.77 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 0.77 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 0.77 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 0.77 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 0.77 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 0.77 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 0.77 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 0.77 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 6/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinflunine SCHEMBL10018503 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL29379199 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL10048181 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL16886954 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL8403 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL19242433 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL16786354 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL21090975 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL21449088 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Vinflunine SCHEMBL21050493 | 1.00 | TUBB4A (0.77) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18343 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-4719420-A1 | TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH ERDAFINITIB | Janssen Pharmaceutica NV (BE) | 2026-04-08 | — | — | EP | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| EP-4705343-A1 | ANTI-HUMAN M-CADHERIN (CDH15) ANTIBODIES, CONJUGATES, AND USES THEREOF FOR DELIVERY OF GENETIC PAYLOADS TO MUSCLE CELLS | Regeneron Pharmaceuticals, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4694935-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY, AND USE THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4688871-A1 | SITE-SPEICFIC ORTHOGONAL BIOCONJUGATE MODALITY AND APPLICATION THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| US-20250387505-A1 | ANTI-FGFR3 ANTIBODY CONJUGATE AND MEDICAL USE THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2025-12-25 | — | — | US | claimed |
| US-20250387481-A1 | PRE-TREATED T CELLS FOR USE AS A MEDICAMENT | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2025-12-25 | — | — | US | claimed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000042003-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000041505-A2 | ANTHRANILIC ACID DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000042022-A1 | BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000042029-A1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000041994-A1 | 4-ARYLAMINO, 4-ARYLOXY, AND 4-ARYLTHIO DIARYLAMINES AND DERIVATIVES THEREOF AS SELECTIVE MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000042002-A1 | SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| EP-0975640-A1 | VINCA ALKALOID ANTIMITOTIC HALOGENATED DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2000-02-02 | — | — | EP | claimed |
| WO-1998045301-A1 | VINCA ALKALOID ANTIMITOTIC HALOGENATED DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 1998-10-15 | — | — | WO | claimed |